Advertisement

Interdisziplinäre Therapie von Knochenmetastasen

  • Johannes Fakler
  • Tilman Todenhöfer
  • Mark Müller
  • Andreas A. Kurth
  • Christian Eberhardt
  • Rainer Fischer
Part of the Fortbildung Osteologie book series (FORTOSTEO, volume 4)

Zusammenfassung

Die Prognose von Patienten mit Knochenmetastasen ist individuell abhängig vom zugrunde liegenden Primarius. In den letzten Jahren ist die Lebenserwartung von Patienten durch die Fortschritte in der systemischen Therapie (Chemotherapie, Immuntherapie, antihormonelle Therapie) und der radioonkologischen Interventionen deutlich verbessert worden. Dieses Kapitel stellt die Anwendung der gängigen Osteologika bei ossärer Metastasierung, die Radionuklidtherapie und chirurgisch-orthopädische Möglichkeiten vor sowie die ethischen Aspekte, die beim Scoring von Patienten mit Knochenmetastasen zu berücksichtigen sind.

Literatur

Literatur zu Abschn. 3.1

  1. Body JJ, Bartl R, Burckhardt P, Delmas PD, Diel IJ, Fleisch H, Kanis JA, Kyle RA, Mundy GR, Paterson AH, Rubens RD (1998) Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 16: 3890–9CrossRefPubMedCentralGoogle Scholar
  2. Body JJ, Casimiro S, Costa L (2015) Targeting bone metastases in prostate cancer: improving clinical outcome. Nat Rev Urol. 12: 340–56CrossRefPubMedCentralGoogle Scholar
  3. Buckwalter JA, Brandser EA (1997) Metastatic disease of the skeleton. Am Fam Physician 55: 1761–8Google Scholar
  4. Carter JA, Joshi AD, Kaura S, Botteman MF (2012) Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours. Pharmacoeconomics 30: 373–86CrossRefPubMedCentralGoogle Scholar
  5. Gartrell BA, Saad F (2014) Managing bone metastases and reducing skeletal related events in prostate cancer. Nat Rev Clin Oncol 11: 335–45CrossRefPubMedCentralGoogle Scholar
  6. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, Hortobagyi GN, Eakle J, Mukai H, Iwata H, Geberth M, Hart LL, Hadji P, El-Hashimy M, Rao S, Taran T, Sahmoud T, Lebwohl D, Campone M, Pritchard KI (2013) Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst 105: 654–63CrossRefPubMedCentralGoogle Scholar
  7. Hofbauer LC, Rachner TD, Coleman RE, Jakob F (2014) Endocrine aspects of bone metastases. Lancet Diabetes Endocrinol 2: 500–12CrossRefGoogle Scholar
  8. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038–44CrossRefPubMedCentralGoogle Scholar
  9. Hussein O, Tiedemann K, Murshed M, Komarova SV (2012) Rapamycin inhibits osteolysis and improves survival in a model of experimental bone metastases. Cancer Lett 314: 176–84CrossRefPubMedCentralGoogle Scholar
  10. Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A (2016) Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer 53: 75–83.CrossRefPubMedCentralGoogle Scholar
  11. McGreevy C, Williams D (2011) Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2: 159–72CrossRefPubMedCentralGoogle Scholar
  12. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449–56Google Scholar
  13. Parker C, Finkelstein SE, Michalski JM, O’Sullivan JM, Bruland Ø, Vogelzang NJ, Coleman RE, Nilsson S, Sartor O, Li R, Seger MA, Bottomley D (2016) Efficacy and safety of radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol Jun 22. pii: S0302–2838 (16)30272-X. doi: 10.1016/j.eururo.2016.06.002. [Epub ahead of print]CrossRefPubMedCentralGoogle Scholar
  14. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzén L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369: 213–23CrossRefPubMedCentralGoogle Scholar
  15. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98: 1735–44CrossRefGoogle Scholar
  16. Sartor O, Coleman R , Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland ØS, Parker C (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15: 738–46CrossRefPubMedCentralGoogle Scholar
  17. Yong M, Jensen AÖ, Jacobsen JB, Nørgaard M, Fryzek JP, Sørensen HT (2011) Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007). Breast Cancer Res Treat 129: 495–503CrossRefPubMedCentralGoogle Scholar

Literatur zu Abschn. 3.2

  1. Baczyk M, Czepczynski R, Milecki P, Pisarek M, Oleksa R, Sowinski J (2007) 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28 (4): 245–250. doi: 10.1097/MNM.0b013e32805b72a0CrossRefGoogle Scholar
  2. Brahme A (2011) Accurate description of the cell survival and biological effect at low and high doses and LET’s. J Radiat Res 52 (4): 389–407. doi: 10.1269/jrr.10129CrossRefPubMedCentralGoogle Scholar
  3. Bruland OS, Nilsson S, Fisher DR, Larsen RH (2006) High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res 12 (20 Pt 2): 6250s-6257s. doi: 10.1158/1078–0432.CCR-06–0841
  4. Bryan JN, Bommarito D, Kim DY, Berent LM, Bryan ME, Lattimer JC, Henry CJ, Engelbrecht H, Ketring A, Cutler C (2009) Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs. J Nucl Med Technol 37 (1): 45–52. doi: 10.2967/jnmt.108.054700CrossRefPubMedCentralGoogle Scholar
  5. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ (2000) Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 31 (5): 578–583CrossRefPubMedCentralGoogle Scholar
  6. Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E, Group EGW (2012) Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23 Suppl 7: vii11–19. doi: 10.1093/annonc/mds232CrossRefPubMedCentralGoogle Scholar
  7. Chow E, van der Linden YM, Roos D, Hartsell WF, Hoskin P, Wu JS, Brundage MD, Nabid A, Tissing-Tan CJ, Oei B, Babington S, Demas WF, Wilson CF, Meyer RM, Chen BE, Wong RK (2014) Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. Lancet Oncol 15 (2): 164–171. doi: 10.1016/S1470–2045 (13)70556–4
  8. Christensen MH, Petersen LJ (2012) Radionuclide treatment of painful bone metastases in patients with breast cancer: a systematic review. Cancer Treat Rev 38 (2): 164–171. doi: 10.1016/j.ctrv.2011.05.008CrossRefPubMedCentralGoogle Scholar
  9. Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014) A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat 145 (2): 411–418. doi: 10.1007/s10549–014–2939–1
  10. Collins C, Eary JF, Donaldson G, Vernon C, Bush NE, Petersdorf S, Livingston RB, Gordon EE, Chapman CR, Appelbaum FR (1993) Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34 (11): 1839–1844Google Scholar
  11. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28 (7): 788–798CrossRefPubMedCentralGoogle Scholar
  12. Dickie GJ, Macfarlane D (1999) Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol 43 (4): 476–479CrossRefPubMedCentralGoogle Scholar
  13. ESMO – European Society for Medical Oncology (2017) EMA issues warning about use of radium-223 dichloride in combination with abiraterone acetate and prednisone or prednisolone. [http://www.esmo.org/Oncology-News/EMA-Issues-Warning-About-Use-of-Radium-223-Dichloride-in-Combination-With-Abiraterone-Acetate-and-Prednisone- or-Prednisolone]
  14. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A (2009) Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27 (15): 2429–2435. doi: 10.1200/JCO.2008.18.9811CrossRefPubMedCentralGoogle Scholar
  15. Hoskin P, Sartor O, O’Sullivan JM, Johannessen DC, Helle SI, Logue J, Bottomley D, Nilsson S, Vogelzang NJ, Fang F, Wahba M, Aksnes AK, Parker C (2014) Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol 15 (12): 1397–1406. doi: 10.1016/S1470–2045 (14)70474–7
  16. Kraeber-Bodere F, Campion L, Rousseau C, Bourdin S, Chatal JF, Resche I (2000) Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med 27 (10): 1487–1493CrossRefPubMedCentralGoogle Scholar
  17. Deutsche Gesellschaft für Nuklearmedizin e.V. (Hrsg) 2014) Leitlinien der Deutschen Gesellschaft für Nuklearmedizin e.V. (DGN): Radionuklidtherapie bei schmerzhaften Knochenmetastasen. http://www.nuklearmedizin.de/leistungen/leitlinien/html/radionuk_ther.php?navId=53
  18. Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R (2000) Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases. Nuklearmedizin Nucl Med 39 (6): 146–151CrossRefPubMedCentralGoogle Scholar
  19. Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28 (8): 623–630. doi: 10.1097/MNM.0b013e32825a6adcCrossRefPubMedCentralGoogle Scholar
  20. Mathe D, Balogh L, Polyak A, Kiraly R, Marian T, Pawlak D, Zaknun JJ, Pillai MR, Janoki GA (2010) Multispecies animal investigation on biodistribution, pharmacokinetics and toxicity of 177Lu-EDTMP, a potential bone pain palliation agent. Nucl Med Biol 37 (2): 215–226. doi: 10.1016/j.nucmedbio.2009.09.004CrossRefPubMedCentralGoogle Scholar
  21. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O’Donoghue J, Larson S, Scher HI (2009) Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol 27 (15): 2436–2442. doi: 10.1200/JCO.2008.20.4164CrossRefPubMedCentralGoogle Scholar
  22. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A (2011) EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59 (4): 572–583. doi: 10.1016/j.eururo.2011.01.025CrossRefPubMedCentralGoogle Scholar
  23. Nair N (1999) Relative efficacy of 32P and 89Sr in palliation in skeletal metastases. J Nucl Med 40 (2): 256–261Google Scholar
  24. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11 (12): 4451–4459. doi: 10.1158/1078–0432.CCR-04–2244
  25. Palmedo H, Guhlke S, Bender H, Sartor J, Schoeneich G, Risse J, Grunwald F, Knapp FF, Jr., Biersack HJ (2000) Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases. Eur J Nucl Med 27 (2): 123–130Google Scholar
  26. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzen L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators A (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. NEJM 369 (3): 213–223. doi: 10.1056/NEJMoa1213755CrossRefPubMedCentralGoogle Scholar
  27. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D (1997) A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer 33 (10): 1583–1591CrossRefPubMedCentralGoogle Scholar
  28. Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G (2007) Clinical benefit of bone-targeted radiometabolic therapy with 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imag 34 (7): 1023–1030. doi: 10.1007/s00259–006–0343–8
  29. Ritter MA, Cleaver JE, Tobias CA (1977) High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature (London) 266 (5603): 653–655CrossRefPubMedCentralGoogle Scholar
  30. Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Vogelzang NJ, O’Bryan-Tear CG, Shan M, Bruland OS, Parker C (2014) Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 15 (7): 738–746. doi: 10.1016/S1470–2045 (14)70183–4
  31. Schoeneich G, Muller SC, Palmedo H (1998) [Indications for nuclear medicine therapy in advanced prostate carcinoma]. Urologe Ausg A 37 (2): 162–166CrossRefPubMedCentralGoogle Scholar
  32. Sciuto R, Festa A, Pasqualoni R, Semprebene A, Rea S, Bergomi S, Maini CL (2001) Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients. Breast Cancer Res Treat 66 (2): 101–109CrossRefPubMedCentralGoogle Scholar
  33. Serafini AN (2000) Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer 88 (12 Suppl): 2934–2939CrossRefPubMedCentralGoogle Scholar
  34. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA (1998) Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16 (4): 1574–1581CrossRefPubMedCentralGoogle Scholar
  35. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, Brill AB, Song H, Howell RW, Akabani G, Committee SM, Bolch WE, Brill AB, Fisher DR, Howell RW, Meredith RF, Sgouros G, Wessels BW, Zanzonico PB (2010) MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy. J Nucl Med 51 (2): 311–328. doi: 10.2967/jnumed.108.058651CrossRefPubMedCentralGoogle Scholar
  36. Shinto AS, Shibu D, Kamaleshwaran KK, Das T, Chakraborty S, Banerjee S, Thirumalaisamy P, Das P, Veersekar G (2014) (1) (7) (7)Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases. J Nucl Med Technol 42 (1): 55–61. doi: 10.2967/jnmt.113.132266CrossRefPubMedCentralGoogle Scholar
  37. Silberstein EB (1993) The treatment of painful osseous metastases with phosphorus-32-labeled phosphates. Semin Oncol 20 (3 Suppl 2): 10–21Google Scholar
  38. Sinzinger H, Palumbo B, Ozker K (2011) The Vienna protocol and perspectives in radionuclide therapy. Q J Nucl Med Mol Imag 55 (4): 420–430Google Scholar
  39. Todenhöfer T, Müller M (2014) Radionuklidtherapie im Behandlungskonzept von Knochenmetastasen. Osteologie 23: 269–274CrossRefGoogle Scholar
  40. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ (2001) Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 357 (9253): 336–341. doi: 10.1016/S0140–6736(00)03639–4
  41. von Moos R, Body JJ, Egerdie B et al. (2013) Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer 21: 3497CrossRefPubMedCentralGoogle Scholar
  42. Wenzl T, Wilkens JJ (2011) Theoretical analysis of the dose dependence of the oxygen enhancement ratio and its relevance for clinical applications. Radiat Oncol 6: 171. doi: 10.1186/1748–717X-6–171
  43. Yuan J, Liu C, Liu X, Wang Y, Kuai D, Zhang G, Zaknun JJ (2013) Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nucl Med 38 (2): 88–92. doi: 10.1097/RLU.0b013e318279bf4dCrossRefPubMedCentralGoogle Scholar

Literatur zu Abschn. 3.3

  1. Boriani S, Weinstein JN, Biagini R (1997) Primary bone tumors of the spine. Terminology and surgical staging. Spine 22: 1036–1044CrossRefGoogle Scholar
  2. Deramond H, Depriester C, Toussaint P, Galibert P (1997) Percutaneous vertebroplasty. Semin Musculoskelet Radiol 285–296CrossRefPubMedCentralGoogle Scholar
  3. Haentjens P, Casteleyn PP, Opdecam P (1993) Evaluation of impending fractures and indications for prophylactic fixation of metastases in long bones: review of the literature. Acta Orthop Belg 59(suppl 1): 6–11Google Scholar
  4. Harrington KD (1986) Impending pathologic fractures from metastatic malignancy: evaluation and management. Instructional Course Lectures 35: 357–381Google Scholar
  5. Hillen TJ, Anchala P, Friedman MV, Jennings JW (2014) Treatment of Metastatic Posterior Vertebral Body Osseous Tumors by Using a Targeted Bipolar Radiofrequency Ablation Device: Technical Note. Radiology 273 (1): 261–267. doi: http://dx.doi.org/10.1148/ radiol.14131664
  6. Hipp JA, Springfields DS, Hayes WC (1995) Predicting pathologic fracture risk in the management of metastatic bone defects. Clin Orthop 312: 120–35Google Scholar
  7. Hong J, Cabe G, Tedrow J, Hipp J, Snyder B (2004) Failure of trabecular bone with simulated lytic defects can be predicted non-invasively by structural analysis. J Orthop Res 22: 479–486CrossRefPubMedCentralGoogle Scholar
  8. Kurth AA, Eberhardt C (2014) Die chirurgisch-orthopädische Behandlung von Knochenmetastasen. Osteologie 23: 281–286CrossRefGoogle Scholar
  9. Mankin HJ, Mankin CJ, Simon MA (1996) The hazards of the biopsy, revisited. Members of the musculoskeletal tumor society. J Bone Joint Surg Am 78: 656–663Google Scholar
  10. Mirels H (1989) Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res 249: 256–64Google Scholar
  11. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2 (8): 584–593CrossRefPubMedCentralGoogle Scholar
  12. Papathanassiou ZG, Petsas T, Papachristou D, Megas P (2011) Radiofrequency ablation of osteoid osteomas: five years experience. Acta Orthopaed Belg 77: 827–33Google Scholar
  13. Patchell RA, Tibbs PA, Regine WF et al. (2005) Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 366 (9486): 643–648CrossRefGoogle Scholar
  14. Phadke DM, Lucas DR, Madan S (2001) Fine-needle aspiration biopsy of vertebral and intervertebral disc lesions: Specimen adequacy, diagnostic utility, and pitfalls. Arch Pathol Lab Med 125: 1463–1468Google Scholar
  15. Piccioli A, Ventura A, Maccauro G, Spinelli MS, Del Bravo V, Rosa MA (2011) Local adjuvants in surgical management of bone metastases. Int J Immunopathol Pharmacol 24 (1) (Suppl 2): 129–32CrossRefPubMedCentralGoogle Scholar
  16. Proschek D, Kurth A, Proschek P, Vogl TJ, Mack MG (2009) Prospective pilot-study of combined bipolar radiofrequency ablation and application of bone cement in bone metastases. Anticancer Research 29: 2787–92Google Scholar
  17. Proschek D, Tonak M, Mack M, Kurth AA (2012) Radiofrequency ablation in experimental bone metastases using a controlled and navigated ablation device. J Bone Oncol 9, 1: 63–66, http://dx.doi.org/10.1016/j.jbo.2012.07.001CrossRefPubMedCentralGoogle Scholar
  18. Tancioni F, Lorenzetti MA, Navarria P et al. (2011) Percutaneous vertebral augmentation in metastatic disease: state of the art. J Support Oncol 9 (1): 4–10CrossRefPubMedCentralGoogle Scholar
  19. Tomita K, Kawahara N, Kobayashi T, Yoshida A, Murakami H, Akamaru T (2001) Surgical strategy for spinal metastases. Spine 26: 298–306CrossRefGoogle Scholar
  20. Wedin R (2001) Surgical treatment for pathological fracture. Acta Orthop Scand Suppl 72: 1.29Google Scholar

Literatur zu Abschn. 3.4

  1. Akashe-Böhme F, Böhme G (2005) Mit Krankheit leben. Von der Kunst, mit Schmerz und Leid umzugehen. Beck´sche Reihe. Beck, MünchenGoogle Scholar
  2. Holle R (1995) Methoden zur Konstruktion und Evaluierung klinischer Scores. Inst. für Med. Biometrie u. Informatik, Abt. Med. Biometrie, Univ HeidelbergGoogle Scholar
  3. Krainer L, Heintel P (2010) Prozessethik. Zur Organisation ethischer Entscheidungsprozesse. Verlag für Sozialwissenschaften, WiesbadenCrossRefGoogle Scholar
  4. Schmidt MC (2008) Griff nach dem Ich? Ethische Kriterien für die medizinische Intervention in das menschliche Gehirn. De Gruyter, BerlinGoogle Scholar
  5. von der Höh NH, Gulow J, Tschöke SK et al (2013) Prognostische Scores bei Wirbelsäulenmetastasen. Orthopäde 42: 725–733CrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  • Johannes Fakler
    • 1
  • Tilman Todenhöfer
    • 2
  • Mark Müller
    • 3
  • Andreas A. Kurth
    • 4
  • Christian Eberhardt
    • 5
  • Rainer Fischer
    • 6
  1. 1.Klinik für Orthopädie, Unfallchirurgie und Plastische ChirurgieUniversitätsklinikum LeipzigLeipzigDeutschland
  2. 2.Klinik für Urologie TübingenEberhard-Karls-Universität TübingenTübingenDeutschland
  3. 3.HeidelbergDeutschland
  4. 4.Abteilung für Orthopädie und UnfallchirurgieAsklepios Klinik BirkenwerderBirkenwerderDeutschland
  5. 5.Orthopädie und UnfallchirurgieAsklepios KlinikLangenDeutschland
  6. 6.Krankenhaus- und AltenheimseelsorgerEvangelisches KrankenhausBergisch GladbachDeutschland

Personalised recommendations